聚(ADP-核糖)聚合酶抑制剂在前列腺癌中应用的近期与未来进展
本综述总结了PARP抑制剂(PARPi)治疗晚期前列腺癌的最新临床试验进展及向早期疾病拓展的潜力,指出奥拉帕利和芦卡帕利已获批用于转移性去势抵抗性前列腺癌单药治疗,PARPi联合雄激素受体通路抑制剂方案也已获批,贫血和乏力为主要不良事件。
要点
- 奥拉帕利和芦卡帕利已获批用于转移性去势抵抗性前列腺癌单药治疗,为前列腺癌首批生物标志物指导的药物适应证。
- 多种PARPi联合雄激素受体通路抑制剂的方案也已获批。
- 贫血和乏力是该类药物临床试验中的主要不良事件,胃肠道毒性常见但通常可控。
核心结论
- PARPi对携带HRR突变的前列腺癌有活性,尤其是携带胚系或体细胞BRCA1/2突变者。
- 仍需进一步优化患者分层策略,尤其是联合治疗策略。
- 未来研究应聚焦于完善预测性生物标志物、改进治疗实施策略,并探索PARPi在疾病更早期阶段的潜在获益。
研究设计与样本
- 本综述纳入检测PARPi治疗晚期前列腺癌的临床试验最新进展及其在更早期疾病背景中新兴作用的文献,并讨论仔细筛选患者和识别额外生物标志物对提高疗效的关键作用。
主要发现
- 奥拉帕利和芦卡帕利已获批作为转移性去势抵抗性前列腺癌的单药治疗,从而确立了前列腺癌中首批生物标志物指导的药物适应证。
- PARPi与雄激素受体通路抑制剂的多种联合方案目前也已获批。
- 临床试验中该类药物相关的主要不良事件为贫血和乏力;胃肠道毒性常见但通常可控。
- PARPi对携带HRR突变的前列腺癌有活性,尤其是携带胚系或体细胞BRCA1/2突变者。
- 将PARPi与前列腺癌其他标准药物联合的多项研究提示可能在更广泛患者群体中有效,但部分数据仍需在更长随访分析中验证。
关键数值与推荐
- 奥拉帕利和芦卡帕利已获批作为转移性去势抵抗性前列腺癌的单药治疗。
- PARPi与雄激素受体通路抑制剂的多种联合方案已获批。
- PARPi对携带HRR突变的前列腺癌有活性,尤其是携带胚系或体细胞BRCA1/2突变者。
- 贫血和乏力是该类药物临床试验中的主要不良事件;胃肠道毒性常见但通常可控。
临床怎么用
- 原文未据此给出推荐。
局限性
- 部分PARPi联合其他标准药物治疗前列腺癌的研究数据仍需在更长随访分析中验证。
- 仍需进一步优化患者分层策略,尤其是联合治疗策略。
- 未来研究应聚焦于完善预测性生物标志物、改进治疗实施策略,并探索PARPi在疾病更早期阶段的潜在获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Advanced prostate cancer (PCa) is enriched for alterations in DNA damage repair genes; poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are a class of drugs that have demonstrated effectiveness in PCa, particularly in tumors with alterations in BRCA1/2 and other homologous recombination repair (HRR) genes, acting through a synthetic lethal mechanism. To prevent or delay drug resistance, and to expand the patient population that can benefit from this class of drug, combination treatment strategies have been developed in preclinical and clinical studies. METHODS: This review examines the latest developments in clinical trials testing PARPi for advanced PCa and their emerging role in earlier disease settings. Furthermore, it discusses the critical role of careful patient selection and identification of additional biomarkers to enhance treatment efficacy. KEY FINDINGS AND LIMITATIONS: Two PARPi (olaparib and rucaparib) have been approved as monotherapy in metastatic castration-resistant PCa, thereby establishing the first biomarker-guided drug indications in PCa. Several combinations of PARPi with androgen receptor pathway inhibitors have now also been approved. Anemia and fatigue are the main adverse events associated with this drug class in clinical trials; gastrointestinal toxicities are common but usually manageble. CONCLUSIONS AND CLINICAL IMPLICATIONS: PARPi are active against PCa with HRR mutations, especially in those with germline or somatic BRCA1/2 mutations. There is still a need to further optimize patient stratification strategies, particularly for combination approaches. Future research should focus on refining predictive biomarkers, improving treatment delivery strategies, and exploring the potential benefits of PARPi in earlier stages of the disease. PATIENT SUMMARY: Here, we summarize the results from clinical trials testing different poly (ADP-ribose) polymerase inhibitors (PARPi), a novel targeted drug class, in prostate cancer. Overall, the data from these trials confirm the efficacy of this drug class in those metastatic prostate cancers that show specific gene alterations, such as mutations in the BRCA1/2 genes. Several studies combining PARPi with other standard drugs for prostate cancer suggest that there may be efficacy in larger patient populations, but some of these data still need validation in longer follow-up analyses.
引用
- Zacchi F, Abida W, Antonarakis ES, et al. Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer. Eur Urol Oncol. 2024. PMID: 39638687. doi:10.1016/j.euo.2024.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。